IRCT20210612051550N1尚未招募3 期
Evaluation of the effect of empagliflozin administration on reduction of cardiovascular complication in diabetic patients after PCI
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with definitive diagnosis of diabetes mellitus type 2 (HbA1c= 6.8%)
- •Consent to participate in the study
排除标准
- •Diabetic ketoacidosis
- •Urinary and genital infections
- •Type 1 diabetes
- •Severe liver failure
- •Existence of malignancy and cancer
- •eGFR 30 < ml/min
研究者
相似试验
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
招募中
3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
已完成
3 期
The effect of empagliflozin laboratory findingsCondition 1: Diabetes Mellitus type 2. Condition 2: Coronary artery disease.Type 2 diabetes mellitusAtherosclerotic heart disease of native coronary arteryI125.1IRCT20190412043247N1Zanjan University of Medical Sciences100